Ascendis Financials for Q1 2026: Revenue and Operating Performance
In the first quarter of 2026, Ascendis (ASND) reported total revenue of EUR 247 million. YORVIPATH contributed EUR 197 million to this figure despite a temporary U.S. free drug program reducing revenue by approximately EUR 15 million.
Tickers: $ASND